Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of gefitinib in treating patients who have
persistent or recurrent endometrial cancer. Biological therapies such as gefitinib may
interfere with the growth of tumor cells and slow the growth of endometrial cancer.